LYCERA
Lycera is a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease Lycera's first-in-class drugs are designed to treat immune disorders. The company's technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway. Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.
LYCERA
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2006-01-01
Address:
Ann Arbor, Michigan, United States
Country:
United States
Website Url:
http://www.lycera.com
Total Employee:
51+
Status:
Active
Contact:
7342333147
Email Addresses:
[email protected]
Total Funding:
85.89 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Clarus Ventures
Clarus Ventures investment in Series A - Lycera
EDF Ventures
EDF Ventures investment in Series A - Lycera
Clarus Ventures
Clarus Ventures investment in Series A - Lycera
InterWest Partners
InterWest Partners investment in Series A - Lycera
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Lycera
Wolverine Venture Fund
Wolverine Venture Fund investment in Venture Round - Lycera
EDF Ventures
EDF Ventures investment in Seed Round - Lycera
Official Site Inspections
http://www.lycera.com
- Host name: 208.91.197.27
- IP address: 208.91.197.27
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Lycera"
Lycera - Crunchbase Company Profile & Funding
Lycera is a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease Lycera's first-in-class drugs are designed to …See details»
Lycera Company Profile 2024: Valuation, Funding
Developer of molecule immunomodulatory medicines designed for the treatment of autoimmune diseases and cancer.See details»
Lycera Company Profile - Office Locations, Competitors, Revenue …
Lycera is a private biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer.See details»
Lycera | VentureRadar
Lycera is a biopharmaceutical company pioneering innovative approaches to the discovery and development of oral medicines for treating autoimmune diseases. The company is targeting …See details»
Lycera - Products, Competitors, Financials, Employees, …
Lycera is a biopharmaceutical company pioneering approaches to the discovery and development of oral medicines for treating autoimmune diseases. Use the CB Insights Platform to explore …See details»
Lycera Corp - Company Profile and News - Bloomberg Markets
Lycera Corporation discovers and develops biopharmaceutical products. The Company offers novel oral medicines for the treatment of autoimmune diseases such as rheumatoid arthritis, …See details»
Lycera - Overview, News & Similar companies | ZoomInfo.com
View Lycera (www.lycera.com) location in Michigan, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Celgene acquires Lycera - 2015-06-09 - Crunchbase
Jun 9, 2015 · Lycera Lycera engages in the development of small-molecule immunomodulators for the treatment of patients with autoimmune diseases. Acquiring Organization: Celgene …See details»
Lycera - Company Profile - Tracxn
Nov 19, 2024 · Lycera - Development of small-molecule immunomodulators for the treatment of patients with autoimmune diseases.. This company is not active anymore. Raised a total …See details»
Lycera - Contacts, Employees, Board Members, Advisors & Alumni
Lycera has 8 board members and advisors, including Laura Carter. Lycera engages in the development of small-molecule immunomodulators for the treatment of patients with …See details»
Ann Arbor's Lycera In Collaboration With Pharma Giant Merck
Feb 12, 2013 · ANN ARBOR -- The Ann Arbor pharma startup Lycera Corp. Tuesday announced a collaboration with pharma giant Merck to discover, develop and commercialize small …See details»
Lycera Announces Initiation of Phase 1/2a Study ARGON of …
Jan 4, 2017 · Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of …See details»
Lycera Announces Presentations of Positive Preclinical Results for …
Mar 18, 2016 · LYC-30937-EC, a first-in-class, oral, gut-directed ATPase modulator, is designed to selectively target and induce cell death (apoptosis) in disease-causing immune cells (T …See details»
Lycera Expands Partnership With Merck; Potential $600-Million Deal
Lycera Corp. recently announced a collaboration agreement with Merck to discover, develop, and commercialize small-molecule therapies directed to selected novel targets being investigated …See details»
Lycera's double-action immuno-oncology drug starts trials
Jan 4, 2017 · Lycera has pushed the first of its RORgamma agonist immuno-oncology drugs — partnered with Celgene — into early-stage clinical testing. Current immuno-oncology drugs are …See details»
Lycera and Celgene Announce an Exclusive Strategic Collaboration …
Jun 9, 2015 · Lycera is a biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer. Based on successful progress of its …See details»
Lycera starts Phase lb combination trial of LYC-55716 for NSCLC
Jan 5, 2018 · Lycera has commenced a Phase lb clinical trial of LYC-55716 in combination with pembrolizumab (Keytruda) to treat patients with metastatic non-small cell lung cancer …See details»
Lycera and Celgene partner to advance development of immune …
Jun 9, 2015 · Biopharmaceutical firm Lycera has entered an exclusive strategic collaboration with Celgene to advance the development of its proprietary pipeline for cancer and immune …See details»
Lycera and Celgene Announce an Exclusive Strategic Collaboration …
Jun 9, 2015 · Transformational collaboration will focus on the advancement of Lycera's innovative pipeline, including Lycera's first-in-class RORgamma agonists for cancer immunotherapy, and...See details»
Lycera and Celgene collaborate to advance cancer drugs - Drug …
Jun 10, 2015 · Lycera has formed of an exclusive global collaboration with Celgene to take forward Lycera’s proprietary pipeline for cancer and immune-mediated diseases. Lycera has …See details»